Previous close | 1.9700 |
Open | 2.0300 |
Bid | 1.8900 x 800 |
Ask | 1.9000 x 800 |
Day's range | 1.8315 - 2.0300 |
52-week range | 1.7900 - 6.8400 |
Volume | |
Avg. volume | 731,504 |
Market cap | 113.898M |
Beta (5Y monthly) | 1.82 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
With the business potentially at an important milestone, we thought we'd take a closer look at Gamida Cell Ltd.'s...
Pfizer's (PFE) ELEVATE UC 52 is the second phase III study on etrasimod for ulcerative colitis to have met primary and key secondary endpoints.
Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.